Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar

By Yin Min Thaung, Charles S. Chasela, Kara W. Chew, Thomas Minior, Aye A. Lwin, Yi Y. Sein, Ndeye Drame, Fadzai Marange, Charles van der Horst, Hnin T. Thwin, Morgan J Freiman, Malini M. Gandhi, Murdo Bijl, Constance Wose King,  Professor Sydney Rosen  Si Thura, Sofiane Mohamed, Thembisile Xulu, Aung Y. Naing, Matthiue Barralon, Clint Cavenaugh, Khin P. Kyi  Professor Ian Sanne  |  | 

Access to hepatitis C virus (HCV) testing and treatment is limited in Myanmar. Weassessed an integrated HIV and viral hepatitis testing and HCV treatment strategy. Sofosbuvir/velpatasvir (SOF/VEL) ± weight-based ribavirin for 12 weeks was provided at three treatment sites in Myanmar and sustained virologic response (SVR) assessed
at 12 weeks after treatment. Participants co-infected with HBV were treated concurrently with tenofovir. Cost estimates in 2018 USD were made at Yangon and Mandalay using standard micro-costing methods.

Publication details